AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KJUN 302 min read$XERS

Xeris Biopharma Holdings, Inc. (XERS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Xeris Biopharma Holdings, Inc. (XERS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. xers-20260629 ☐ 0001867096 0001867096 2026-06-29 2026-06-29 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Jun

Original reporting
SEC EDGAR 8-K
Published Jun 30, 2026, 8:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$XERS
Neutral
medium confidence
Mentioned
$XERS
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$XERSNeutralLow
01

Why it matters

The filing adds one independent director (Class III) and updates board leadership structure (CEO as Chair; Lead Independent Director designated). It also discloses initial and ongoing non-employee director equity compensation under the company program.

02

Market read

Traders may monitor for follow-on signals (committee assignments, strategic updates) but the 8-K itself is primarily governance/compensation disclosure.

03

What to watch

Compensation details (initial equity grant ~ $450k; future annual grants ~ $300k) are disclosed, but vesting/terms are standard and unlikely to drive valuation without accompanying strategy changes.

Relevance 6/10Novelty 4/10Timing: after-hours/filing update from SEC EDGAR on June 30, 2026

Background

This is an SEC Form 8-K (Item 5.02) reporting director/officer changes and related compensatory arrangements.

Company-level read

Ticker impact

$XERSNeutralMedium confidence
Context

Xeris Biopharma appointed Dr. Nerissa Kreher to its board and changed board leadership (CEO as Chair, Persky as Lead Independent) effective July 1, 2026.

Expected impact

Low likelihood of a sustained move; any reaction is likely limited to governance-news sentiment around the filing/PR.

Evidence & confidence

The 8-K discloses director appointment, committee status (none yet), and compensation grant value, but provides no operational, financial, or strategic guidance changes.

Market effects

Sector

Minimal; governance changes at a single small/mid-cap biotech typically do not reset sector risk premia.

Regional

Minimal; Nasdaq-listed company-specific filing.

Global

Minimal; no cross-border deal/regulatory action disclosed.

Counterpoint

What could challenge this read

The appointment could be a signal of upcoming clinical/regulatory focus, but the filing provides no such roadmap—so the market may overreact initially.

Key entities

  • company
    Xeris Biopharma Holdings, Inc.

    Nasdaq-listed biotech filing reporting board expansion, director appointment, and board leadership changes.

  • person
    Nerissa Kreher, M.D.

    Appointed to fill a board vacancy effective July 1, 2026; independent under Nasdaq standards; no committee assignments yet.

  • person
    John Shannon

    CEO appointed Chairperson of the Board effective July 1, 2026.

  • person
    Marla S. Persky

    Designated Lead Independent Director effective July 1, 2026.

Read at source← All news

Related articles

AUG 6
$XERSMed

Xeris Biopharma Holdings, Inc. (XERS): Results of Operations and Financial Condition

Xeris Biopharma Holdings, Inc. (XERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh991q22026earningsrelease.htm EX-99.1 Document Exhibit 99.1 XERIS BIOPHARMA REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS Total revenue increased to over $92 million Net product revenue increased 34% year-over-year to over $91 million Recorlev net revenue increased 81

SEC EDGAR 8-K6 min
AUG 9
$ITWMed

Illinois Tool Works Authorizes $6 Bln Buyback

Illinois Tool Works (ITW) said its board authorized a new share repurchase program of up to $6 billion. The board also approved a 7% increase in its regular annual cash dividend to $6.88 per share, effective with the Q4 dividend of $1.72 payable Oct. 9, 2026. ITW closed at $296.66 on Friday.

rttnews.com2 min
AUG 9
$JNJMed

Money talcs: Why J&J offered $5.5bn to end cancer cases

Johnson & Johnson is offering $5.5 billion to settle most of more than 70,000 pending talc-related cancer lawsuits, according to the company. Claims allege ovarian cancer or mesothelioma linked to asbestos-contaminated talc. J&J denies wrongdoing and says cases lack merit. Prior orders include $966m (LA) and $1.5bn (Baltimore), with appeals planned.

rte.ie6 min
AUG 9
$AAPLMed

Trump Tariff Refunds Just Topped $100 Billion, and These Companies Are Receiving Some of the Largest Checks

The U.S. Supreme Court invalidated Trump IEEPA tariffs, leaving the administration to refund about $166 billion. By Aug. 4, refunds exceeded $100 billion. Apple received $2.19 billion, Amazon $600 million, and others including Walmart ($2.4B), Ford ($1.3B), GM ($500M), and Costco (~$2B) are expected to receive large checks. New Section 301 tariffs may affect prices.

yahoo.com6 min
AUG 8
$MTZMed

Is MasTec’s Debt Raise and Upgraded Guidance Altering The Investment Case For MasTec (MTZ)?

MasTec (MTZ) completed a $647.76 million fixed-rate senior unsecured notes offering with a 5.85% coupon due Sept. 30, 2036. The company reported Q2 2026 sales of $4,373.55 million and net income of $130.12 million, and raised full-year 2026 revenue guidance to $18.2 billion and GAAP net income to $539 million, citing balance-sheet flexibility and governance updates.

simplywall.st6 min